Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma

American Journal of Pathology

Volumn 151, Issue 6, 1997, Pages 1767-1774

  El Naggar, Adel K ^a   Lai, Syeling ^a   Clayman, Gary ^a   Lee, J Jack ^a   Luna, Mario A ^a   Goepfert, Helmuth ^a   Batsakis, John G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GENETICS; CLINICAL ARTICLE; COHORT ANALYSIS; DNA DETERMINATION; GENE ACTIVITY; GENE EXPRESSION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; METHYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030708545     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440
2. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDk4. Nature 1993, 366:704-707
3. Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D: Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995, 267:249-252
4. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D: Frequency of homozygous deletion at p 16/ CDKN2 in primary human tumors. Nature Genet 1995, 11:210-212
5. Liggett WH, Sewell DA, Rocco J, Ahrendt SA, Koch W, Sidransky D: p 16 and p 16β are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res 1996, 56:4119-4123
6. Nakagawa K, Conrad NK, Williams JP, Johnson BE, Kelley MJ: Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene 1995, 11: 1843-1851
7. Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, Yamamouri S, Hayashi Y: Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 1995, 86:1269-1275
8. Reed JA, Loganzo F, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdang JK, Shiel MJ, Haluska FG, Fountain JW, Albino AP: Loss of expression of the p16/cyclin dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995, 55:2713-2718
9. Southgate J, Proffitt J, Roberts P, Smith B, Selby P: Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines. Br J Cancer 1995, 72:1214-1218
10. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, Riet P, Blangrund JE, Sidransky D: Rates of p16(MTS1) mutations in primary tumors with 9p loss. Science 1994, 265:415-417
11. Yendall WA, Crawford RY, Ensley J, Robbins KC: MTS1/CDk4l is altered in cell lives derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis 1994, 15:2683-2686
12. Zhang S-Y, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL: Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell liens than in primary tumors of the head and neck. Cancer Res 1994, 54:5050-5053
13. Lo KW, Huang DP, Lau K-M: p16 gene alterations in nasopharyngeal carcinoma. Cancer Res 1995, 55:2039-2043
14. Matsuda H, Konishi N, Hiasa Y, Hayashi I, Tsuzuki T, Tao M, Kitahori Y, Yoshioka N, Kirita T, Sugimura M: Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. J Oral Pathol Med 1996, 25:232-238
15. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D: High frequency of p16 (CDKN2)MTS-11 INk4A) inactivations in head and neck squamous cell carcinoma. Cancer Res 1996, 56:3630-3633
16. Sun Y, Hildesheim A, Lanier AEP, Cao Y, Yao K-T, Raab-Traub N, Yang C-S: No point mutation but decreased expression of the p16/ MTS1 tumor suppressor gene in nasopharyngeal carcinomas. Oncogene 1995, 10:785-788
17. Larsen G-J: p16INK4a; a gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression. Oncogene 1996, 12:2041-2044
18. Tsunashima K, Endo Y, Asakura H, Kanda H, Nomura K, Kitagawa T, Kominami R: A novel clonality assay for the mouse: application to hepatocellular carcinomas induced with diethylnitrosamine. Mol Carcinogen 1996, 15:33-37
19. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen TD, Beart RW, Van Turnout JM, Jones PA: Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995, 55: 4531-4535
20. Singer-Sam J, Yang TP, Mori N, Tanguay RL, Le Bon JM, Flores JC, Riggs AD: DNA methylation in the 5′ region of the mouse PGK-1 gene and a quantitative PCR assay for methylation. Nucleic Acid Methylation, vol. 128. Edited by Clawson GA, Willis DB, Weissbach A, Jones PA. New York, Alan R Liss, pp 285-289, 1990
21. Campbell IG, Beynon G, Davis M, Englefield P: LOH and mutation analysis of CDKN2 in primary human ovarian cancers, Int J Cancer 1995, 63:222-225
22. Flores JF, Walker GJ, Glendening JM, Haluska FG, Castresana JS, Rubio M-P, Pastorfide GC, Boyer LA, Kao WH, Bulyk ML, Barnhill RL, Hayward NK, Housman DE, Foutain JW: Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 1996, 56:5023-5032
23. Komiya A, Suzuki H, Aida S, Yatani R, Shimazaki J: Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res 1995, 86:622-625
24. Shimizu T, Sekiya T: Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers. Int J Cancer 1995, 63:616-620
25. Brenner AJ, Paladug A, Wang H, Olopade OI, Dreyling MH, Aldo CM: Preferential loss of expression of p16INK4A rather than p19ARF in breast cancer. Clin Cancer Res 1996, 2:1993-1998
26. Mao L, Merlo A, Bedi G, Shapiro GL, Edward CD, Rollins BJ, Sidransky D: A novel p16INK4 transcript. Cancer Res 1995, 55:2995-2997
27. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A: Complex structure and regulation of the p16(MTS1) locus. Cancer Res 1995, 55:2988-2994
28. Herman JG, Merlo A, Mao L, Lapidus RG, Issa J-P J, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995, 55:4525-4530
29. Li Y-J, Hoang H-X, Delattre J-Y, Poisson M, Thomas G, Hamelin R: Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16(MTS1) genes in gliomas. Oncogene 1995, 11:597-600
30. Uzawa K, Suzuki H, Yokoe H, Tanzawa H, Sato K: Mutational state of P16/CDKN2 and VHL genes in squamous cell carcinoma of the oral cavity. Int J Oncol 1995, 7:895-899
31. Heinzel PA, Balaram P, Bernard HU: Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betal quid chewers. Int J Cancer 1996, 68:420-423
32. Lo KW, Cheung S-T, Leung S-F, Hasselt AV, Tsang Y-S, Mak K-F, Chung Y-F, Woo JKS, Lee JCK, Huang DP: Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 1996, 56:2721-2725
33. Igaki H, Sasaki H, Tachimori Y, Kato H, Watanabe H, Kimura T, Harada Y, Sugimura T, Tarada M: Mutations frequency of the p 16/ CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res 1995, 55:3421-3423
34. Yang R, Gombart AF, Serrano M, Koeffler HP: Mutational effects on the p16INk4a tumor suppressor protein. Cancer Res 1995, 55:2503-2506
35. Jones AP: DNA methylation errors and cancer. Cancer Res 1996, 56:2463-2467
36. Otterson GA, Khleif SA, Chen W, Coxon AB, Kaye FJ: CDKN2 gene silencing in lung by DNA hypermethylation and kinetics of p16INk4 protein induction by 5-aza,2-deoxycytidine. Oncogene 1995, 11: 1211-1216
37. Nagatake M, Osada H, Kondo M, Uchida K, Nishio MN, Shimokatoa K, Takahashi T, Takahashi T: Aberrant hypermethylation at the bcl-2 locus at 18q21 in human lung cancers. Cancer Res 1996, 56:1886-1891
38. Thoraval D, Asakawa J-I, Wimmer K, Kuick R, Lamb B, Richardson B, Ambros P, Glover T, Hanash S: Demethylation of repetitive DNA sequences in neuroblastoma. Genes Chromosomes Cancer 1996, 17:234-244
39. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancer. Nature Med 1995, 1:686-692
40. Enders GH, Koh J, Missero C, Rustgi AK, Harlow E: p16 inhibition of transformed and primary squamous epithelial cells. Oncogene 1996, 12:1239-1245
41. Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen ME, Rollins BJ: Multiple mechanisms of p16INk4A inactivation in non-small cell lung cancer cell lines. Cancer Res 1995, 55:6200-6209
42. Tamimi Y, Bringuier PP, Smit F, Bokhoven AV, Abbas A, Debruyne FMJ, Schalken JA: Homozygous deletions of p16INK4 occur frequently in bilharziasis-associated bladder cancer. Int J Cancer 1996, 68:183-187
43. Bird A: The essentials of DNA methylation. Cell 1992, 70:5-8
44. Serrano A, Garcia A, Abril E, Garrido F, Ruiz-Cabello F: Methylated CpG points identified within MAGE-1 promoter are involved in gene expression. Int J Cancer 1996, 68:464-470